These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11843850)

  • 1. Evaluation of monoclonal antibody MIB-1 in the mammary epithelium adjacent to fibroadenomas in premenopausal women treated with tamoxifen.
    de Sousa JA; de Seixas MT; de Lima GR; Baracat EC; Gebrim LH
    Breast J; 2001; 7(6):392-7. PubMed ID: 11843850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a half dose of tamoxifen on proliferative activity in normal breast tissue.
    Bernardes JR; Nonogaki S; Seixas MT; Rodrigues de Lima G; Baracat EC; Gebrim LH
    Int J Gynaecol Obstet; 1999 Oct; 67(1):33-8. PubMed ID: 10576237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of tamoxifen on PCNA expression in fibroadenomas.
    Bernardes JR; Seixas MT; Lima GR; Marinho LC; Gebrim LH
    Breast J; 2003; 9(4):302-6. PubMed ID: 12846865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the ultrasonographic volume of breast fibroadenomas in women treated with tamoxifen.
    Viviani RS; Gebrim LH; Baracat EC; De Lima GR
    Minerva Ginecol; 2002 Dec; 54(6):531-5. PubMed ID: 12432338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of low dose tamoxifen on normal breast tissue from premenopausal women.
    de Lima GR; Facina G; Shida JY; Chein MB; Tanaka P; Dardes RC; Jordan VC; Gebrim LH
    Eur J Cancer; 2003 May; 39(7):891-8. PubMed ID: 12706357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tamoxifen on the breast in the luteal phase of the menstrual cycle.
    Uehara J; Nazário AC; Rodrigues de Lima G; Simões MJ; Juliano Y; Gebrim LH
    Int J Gynaecol Obstet; 1998 Jul; 62(1):77-82. PubMed ID: 9722130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of estrogen and progesterone receptors in non-neoplastic breast tissue of women of reproductive age exposed to tamoxifen and raloxifene: a randomized, double-blind study.
    Rosal MA; da Silva BB
    Breast Cancer Res Treat; 2011 Feb; 125(3):797-801. PubMed ID: 21184272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of raloxifene on normal breast tissue from premenopausal women.
    da Silva BB; Lopes IM; Gebrim LH
    Breast Cancer Res Treat; 2006 Jan; 95(2):99-103. PubMed ID: 16205837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of Bax protein in normal tissue of premenopausal women treated with raloxifene].
    Furtado-Veloso AM; Lopes IM; Lopes-Costa PV; Santos LG; Silva BB
    Rev Bras Ginecol Obstet; 2008 Apr; 30(4):177-81. PubMed ID: 19142489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
    Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
    Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of Ki-67 and Bcl-2 biomarkers in normal breast tissue from women of reproductive age treated with raloxifene.
    Lima MA; da Silva BB
    Arch Gynecol Obstet; 2012 Jan; 285(1):223-7. PubMed ID: 21573987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of human mammary fibroadenoma by Ki-67 index in the follicular and luteal phases of menstrual cycle.
    Rego MF; Navarrete MA; Facina G; Falzoni R; Silva R; Baracat EC; Nazario AC
    Cell Prolif; 2009 Apr; 42(2):241-7. PubMed ID: 19317807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
    Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
    Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogenic activity of tamoxifen on normal mammary parenchyma in the luteal phase of the menstrual cycle.
    Facina G; de Lima GR; Simões MJ; Novo NF; Gebrim LH
    Int J Gynaecol Obstet; 1997 Jan; 56(1):19-24. PubMed ID: 9049690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of tamoxifen on the proliferative activity of fibroadenomas.
    Bernardes JR; Seixas MT; Gebrim LH
    Int J Gynaecol Obstet; 2002 May; 77(2):155-6. PubMed ID: 12031568
    [No Abstract]   [Full Text] [Related]  

  • 16. Timing of adjuvant surgical oophorectomy in the menstrual cycle and disease-free and overall survival in premenopausal women with operable breast cancer.
    Love RR; Laudico AV; Van Dinh N; Allred DC; Uy GB; Quang le H; Salvador JD; Siguan SS; Mirasol-Lumague MR; Tung ND; Benjaafar N; Navarro NS; Quy TT; De La Peña AS; Dofitas RB; Bisquera OC; Linh ND; To TV; Young GS; Hade EM; Jarjoura D
    J Natl Cancer Inst; 2015 Jun; 107(6):djv064. PubMed ID: 25794890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide.
    Johansson H; Bonanni B; Gandini S; Guerrieri-Gonzaga A; Cazzaniga M; Serrano D; Macis D; Puccio A; Sandri MT; Gulisano M; Formelli F; Decensi A
    Breast Cancer Res Treat; 2013 Dec; 142(3):569-78. PubMed ID: 24241787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.
    Ellmén J; Hakulinen P; Partanen A; Hayes DF
    Breast Cancer Res Treat; 2003 Nov; 82(2):103-11. PubMed ID: 14692654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen down-regulates CaMKII messenger RNA levels in normal human breast tissue.
    Da Silva ID; Dias-Netto E; Villanova FE; Yamamoto L; Baracat EC; Lima GR; Gebrim LH
    Clin Exp Obstet Gynecol; 2004; 31(3):204-8. PubMed ID: 15491065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
    Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
    Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.